Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 25:13:151-159.
doi: 10.2147/BCTT.S245024. eCollection 2021.

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Anna S Linehan  1 , Orla M Fitzpatrick  1 , Patrick G Morris  1   2
Affiliations
Review

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Anna S Linehan et al. Breast Cancer (Dove Med Press). .

Abstract

Trastuzumab deruxtecan is a novel antibody-drug conjugate for the treatment of advanced solid tumors, including breast cancer, which overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2). The novel structure of this exciting new agent means that it can deliver a highly potent cytotoxic agent to HER2-expressing tissues resulting in selective killing of cancer cells. In phase I and II trials, trastuzumab deruxtecan has shown impressive response rates in heavily pretreated populations, including patients who had received prior treatment with trastuzumab emtansine, another highly active antibody-drug conjugate. The most common side effects are gastrointestinal and hematological. Importantly, a high rate of interstitial lung disease was seen in early trials, but this appears manageable in most patients with corticosteroids. In light of its efficacy, this promising new drug may change the treatment paradigm of HER2-positive breast cancer.

Keywords: DS8201; HER2; antibody-drug conjugate; trastuzumab deruxtecan; trastuzumab emtansine.

PubMed Disclaimer

Conflict of interest statement

PG Morris has received travel support and honoraria from Roche; travel support from Novartis and Amgen; reports personal fees from Astellas and Pfizer, grants from Teva, BMS, Astra Zeneca, and Genomic Health, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Relative frequency of side effects of antibody-drug conjugates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM200103153441101 - DOI - PubMed
    1. Deluche E, Antoine A, Bachelot T, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020;129:60–70. doi:10.1016/j.ejca.2020.01.016 - DOI - PubMed
    1. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs. 2012;23:765–776. doi:10.1097/CAD.0b013e328352d292 - DOI - PubMed
    1. Gleeson JP, Keegan NM, Morris PG. Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer. Expert Opin Biol Ther. 2018;18:251–262. doi:10.1080/14712598.2018.1410132 - DOI - PubMed
    1. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2014. doi:10.1056/NEJMoa1413513 - DOI - PMC - PubMed